FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “AREV Announces Major Advancement in Extraction Scalability and Throughput.”
AREV Brands International Ltd. (CSE: AREV) is pleased to announce that it has modified its sub critical “FFE” Fast Freeze Extraction systems to be fully scaleable to handle tonnes of biomass on a continuous bases and has developed a patentable method that increases the ability to separate waxes from biomass on the fly.
AREV Brands International Ltd. produces and delivers functional compounds and ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of terpenes, cannabinoids and flavonoids. These premium ingredients and formulations are used in products targeted for sale in the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV innovates through extraction to produce extracts from specific selected plant and exude from trees that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.
Legalization efforts, which are ever present within the cannabis industry, have steadily attracted new consumers each year. In particular, Baby Boomers have seen a large influx of users over recent years; In a survey by MJ Freeway and New Frontier Data, U.S. sales by consumers 55 years or older have increased by 50% since 2015. These consumers alone now account for 29% of medical sales and a quarter of all sales. Currently, the U.S. represents the largest cannabis marketplace, primarily due to states that have already legalized recreational cannabis such as California and Colorado. Since 2015, retail flower prices have fallen significantly as the price per ounce dropped by 25% due to a 40% drop in consumer demand. On the other hand, the concentrate segment is garnering attention as shares of the concentrate market has grown by 138% since 2015, from 16% of all retail sales to 38% in late 2018. Additionally, while 60% of consumers in the survey said they spend less than USD 50 each time they purchase cannabis-based products, many of these consumers purchase more products multiple times within a month, with nearly half of the consumers surveyed stating they spend more than USD 100 per month on cannabis. In combination, all these factors are further propelling the cannabis market. Additionally, the market is also expected to grow pending on international legalization efforts, where most of the countries currently examining the plant are expected to follow a medical legalization path, while also prompting other countries to examine the market. According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016. By 2023, the market is expected to reach USD 65 Billion, growing at a CAGR of 37% during the forecasted period. AREV Brands International Ltd. (CSE: AREV), Aleafia Health Inc. (OTC: ALEAF) (TSX: ALEF), Lifestyle Delivery Systems, Inc. (OTC: LDSYF) (CSE: LDS), InMed Pharmaceuticals, Inc. (OTC: IMLFF) (TSX: IN), MYM Nutraceuticals Inc. (OTC: MYMMF) (CSE: MYM)
The cannabis industry has grown tremendously over the past few years, however, the plant still remains federally enforced in almost every country. So far, cannabis remains strictly regulated due to its marijuana derivative, which grants consumers psychoactive effects stemming from its THC compound. However, Harvard’s Medical School publishing organization has cited various studies which showed that CBD can potentially be an option for treating various medical conditions such as chronic pain, anxiety, inflammation, and notably epilepsy. Strong evidence of effective CBD treatments for childhood epilepsy such as Dravet syndrome and Lennox-Gastaut syndrome have even led the U.S. Food and Drug Administration to legalize Epidiolox, which the first ever cannabis-based drug to be approved by the FDA. However, the FDA has not moved to classify cannabis as a registered medicine for other treatments due to the lack of large-scale clinical trials. However, companies and researchers are keen to keep expanding and improving studies to further add credibility to the CBD compound. “CBD has a number of known properties beneficial to the human condition, and research is just beginning,” Aster Farms President Sam Ludwig told Civilized. “There are two markets for CBD: as a supplement, mild pain reliever and relaxant, and in larger doses, as a truly beneficial remedy for a variety of serious illnesses. There is no doubt it will be dominant supplement for years to come. CBD-heavy flower can be a very effective relaxant for both mind and body. However, people looking for CBD only will find the cleanest and most focused relief in the form of tinctures and capsules. We think the CBD flower market is a trend and will give way to the more concentrated forms. Like an Omega-3 for the body and mind.”
For more information, please visit: AREV Brands International Ltd.
For more corporate news on AREV Brands International Ltd., check out the Buzz on the Street
About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.